Please assess the completion status of the following clinical trial:

Trial Title: Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent~* Male or female Chinese subjects who are between 18 to 65 years of age inclusive.~* Have moderate or severe wrinkles of vertical glabellar lines (Grade 2 or 3) at maximum frown at baseline (Day 1), as assessed by the subject using SSA.~* Have moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at baseline (Day 1), as assessed by the Investigator using ILA.~* Be Botulinum Toxin (BTX) naïve or have received their most recent BTX-A treatment more than 1 year prior to screening.~* Have a negative pregnancy test~* Have an understanding of the study~Exclusion Criteria:~* Any prior surgery affecting corrugator supercilii, prior blepharoplasty or brow lift, dermal resurfacing, or any prior cosmetic procedures or scars within 36 months.~* Any prior treatment with permanent fillers in the upper face.~* Any prior treatment with nonpermanent dermal fillers in the upper face within the past 3 years and/or skin abrasions/resurfacing, photorejuvenation or skin/vascular laser intervention within the past 12 months.~* Any planned facial cosmetic surgery or procedures during the study period.~* Lack of capacity to frown.~* Facial conditions that could affect safety or efficacy results.~* History of facial nerve palsy.~* Marked asymmetry; ptosis; excessive dermatochalasis; deep dermal scarring; thick sebaceous skin; photodamage etc.~* Presence of any condition that could affect the safety, conduct or outcome of the study.~* Any subjects who have any psychiatric illness or are taking antidepressant, anxiolytic or antipsychotic medication.~* Pregnant and/or lactating female subjects.~* Female subjects of childbearing potential not willing to use contraceptive measures throughout the course of the study.~* History of drug or alcohol abuse.~* Treatment with an experimental drug or device within 30 days prior to screening for this study and during the conduct of this study.~* Requirement for BTX injection to site(s) for disorders other than glabellar lines.~* Known allergy or hypersensitivity to BTX.~* Any medical condition or laboratory finding from central laboratory results.~* The subject is unable and/or unwilling to comply fully with the protocol and the study.~* Mental incapacity, unwillingness or language barriers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- AbobotulinumtoxinA (Type: EXPERIMENTAL): Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
- OnabotulinumtoxinA (Type: ACTIVE_COMPARATOR): Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
- AbobotulinumtoxinA Placebo (Type: PLACEBO_COMPARATOR): Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
- OnabotulinumtoxinA Placebo (Type: PLACEBO_COMPARATOR): Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete